Manulife China Bank Life (MCBL), the strategic alliance between Manulife Philippines and China Banking Corporation, is expanding access to cancer care solutions through ManulifeMOVE Cancer Care, a program designed to help customers take a more proactive approach to their health and support longer, healthier lives. As part of the program, eligible customers will have access to Guardant Health’s Shield™ multi-cancer detection (MCD) laboratory developed test (LDT), following Manulife’s exclusive partnership with Guardant Health announced earlier this year. The offering will also soon be available through Manulife Philippines.
Under Manulife’s exclusive partnership with Guardant Health, Inc. a leading precision oncology company—Manulife became the first insurer in Asia to offer the Shield MCD test to customers in Hong Kong, Singapore, and the Philippines. The program expands access to innovative, proven health solutions at a time when cancer remains one of the country’s top causes of death and a significant barrier to longevity for Filipino families. This partnership aligns with the Manulife Longevity Institute, a global research, thought leadership, innovation, advocacy, and community investment platform that aims to advance action on helping people live longer, healthier, and more financially secure lives.
This program is powered by Manulife’s partnership with AC Health, a leading integrated healthcare network in the Philippines. At the heart of the network is Healthway Cancer Care Hospital (HCCH)—the Philippines’ first dedicated and comprehensive cancer hospital. This collaboration between the parties brings together Manulife’s ambition to become the most trusted partner for health, wealth, and longevity, HCCH’s expertise across the full spectrum of cancer care from early cancer detection and diagnosis to advanced treatment and survivorship, and Guardant Health’s commitment to helping individuals live longer and healthier lives through blood-based cancer testing.
“Far too many Filipino families are confronted with life‑altering decisions only after cancer is detected too late, when options are limited and financial pressures intensify,” said Rahul Hora, President and Chief Executive Officer, Manulife Philippines. “By bringing Shield MCD to eligible customers of Manulife Philippines and MCBL, we’re helping move that decision point earlier by encouraging timely medical conversations and better-informed choices. This can help reduce treatment complexity and cost over time, while we strengthen health and longevity outcomes for more Filipinos.”
With just a blood draw, the Shield MCD test screens for 10 of the most common cancers, many of which have high mortality rates in Asia and the Philippines. The test received Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA) in June 2025*1.
“We are proud to deepen our partnership with Manulife by bringing the Shield MCD test to their customers in the Philippines,” said Simranjit Singh, Chief Executive Officer, Guardant Health AMEA. “Cancer remains one of the most pressing health challenges for Filipinos, and Shield MCD offers a powerful new way to tackle this—detecting multiple cancers through a single blood draw. This collaboration underscores our shared dedication to putting innovative health solutions within reach, and we look forward to the difference we can make together in the Philippines.”
“Wider access to early, convenient screening can help more Filipino families take a proactive approach to their health and support their journey toward longer, healthier lives,” said Amy Gochuico, President and Chief Executive Officer, MCBL. “Through our extensive bancassurance network, we are helping bring innovations like Shield MCD closer to more communities, supporting a more proactive and continuous approach to cancer care.”
“We believe one of the greatest opportunities in cancer care is identifying risk and disease earlier, before symptoms appear and treatment becomes more complex,” said Dr. Ramy Roxas, Chief Operating Officer of Healthway Cancer Care Hospital. “We strongly encourage Filipinos to be proactive about their health and participate in appropriate cancer screening, as early detection can significantly improve outcomes and expand treatment options. At Healthway Cancer Care Hospital, our goal is to support patients across the entire cancer journey—from prevention and early detection to diagnosis, treatment, and survivorship.”
Eligible customers of MCBL, and soon, of Manulife Philippines, will be contacted by their financial advisor or financial sales associate to learn more about the Shield MCD test.
* The FDA Breakthrough Device designation referenced includes eight cancer types—bladder, colorectal, esophageal, gastric, liver, lung, ovarian, and pancreatic cancer1
1 Guardant Health. FDA Grants Breakthrough Device Designation to Guardant Healthʼs Multi-Cancer Detection (MCD) Test. Published June 3, 2025. Accessed 28 May, 2026. https://investors.guardanthealth.com/press-releases/press-releases/2025/FDA-Grants-Breakthrough-Device-Designation-to-Guardant-Healths-Shield-Multi-Cancer-Detection-MCD-Test/default.aspx
